Hanwen Zhang

TL;DR: Improved sensitivity; direct correlation of PET signal with an established biomarker (CD68); ability to readily quantify the PET signal, perform whole-body vascular surveys, and spatially localize and follow the trireporter by microscopy; and clinical translatability of the agent given similarities to magnetic resonance imaging probes in clinical trials are established.

TL;DR: Somatostatin antagonist radiotracers are preferable over agonists for the in vivo targeting of sst3- or sst2-expressing tumors, and antagonists for other peptide receptors need to be evaluated in nuclear oncology as a result of this paradigm shift.

TL;DR: This study demonstrates that 67/68Ga-DOTA-octapeptides show distinctly better preclinical, pharmacological performances than the 111In-labelled peptides, especially on sst2-expressing cells and the corresponding animal models, and may be excellent candidates for further development for clinical studies.

TL;DR: The potential of identifying specific molecules against tumor cells or tumor microenvironments to thwart the development of metastatic disease and improve the prognosis of breast cancer patients is discussed.

TL;DR: Results reveal a novel HIF-1α/lnc RNA BCRT1/miR-1303/PTBP3 pathway for breast cancer progression and suggest that lncRNA B CRT1 might be a potential biomarker and therapeutic target for breast cancers.